Evidence map›Paper›PMID 24663284›Full record

ArticlePloS one2014

⁹⁹mTcO₄--, auger-mediated thyroid stunning: dosimetric requirements and associated molecular events.

Béatrice Cambien, Philippe R Franken, Audrey Lamit, Thibault Mauxion, Peggy Richard-Fiardo, Julien Guglielmi, Lydie Crescence, Bernard Mari, Thierry Pourcher, Jacques Darcourt and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. ImprovingInternational journal of nanomedicine · 2019
    Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Béatrice CambienLaboratoire TIRO, UMRE 4320, iBEB, DSV, CEA, Nice, France; Université de Nice-Sophia Antipolis, Nice, France; Centre Antoine Lacassagne, Department of nuclear medicine, Nice, France.
Philippe R FrankenLaboratoire TIRO, UMRE 4320, iBEB, DSV, CEA, Nice, France; Université de Nice-Sophia Antipolis, Nice, France; Centre Antoine Lacassagne, Department of nuclear medicine, Nice, France.
Audrey LamitLaboratoire TIRO, UMRE 4320, iBEB, DSV, CEA, Nice, France; Université de Nice-Sophia Antipolis, Nice, France; Centre Antoine Lacassagne, Department of nuclear medicine, Nice, France.
Thibault MauxionUMR 1037 INSERM/UPS, Centre de Recherche en Cancérologie, Toulouse, France.
Peggy Richard-FiardoLaboratoire TIRO, UMRE 4320, iBEB, DSV, CEA, Nice, France; Université de Nice-Sophia Antipolis, Nice, France; Centre Antoine Lacassagne, Department of nuclear medicine, Nice, France.
Julien GuglielmiLaboratoire TIRO, UMRE 4320, iBEB, DSV, CEA, Nice, France; Université de Nice-Sophia Antipolis, Nice, France; Centre Antoine Lacassagne, Department of nuclear medicine, Nice, France.
Lydie CrescenceLaboratoire TIRO, UMRE 4320, iBEB, DSV, CEA, Nice, France; Université de Nice-Sophia Antipolis, Nice, France; Centre Antoine Lacassagne, Department of nuclear medicine, Nice, France.
Bernard MariUniversité de Nice-Sophia Antipolis, Nice, France; Institut de Pharmacologie Moléculaire et Cellulaire-IPMC, CNRS UMR 7275, Sophia Antipolis, France.
Thierry PourcherLaboratoire TIRO, UMRE 4320, iBEB, DSV, CEA, Nice, France; Université de Nice-Sophia Antipolis, Nice, France; Centre Antoine Lacassagne, Department of nuclear medicine, Nice, France.
Jacques DarcourtLaboratoire TIRO, UMRE 4320, iBEB, DSV, CEA, Nice, France; Université de Nice-Sophia Antipolis, Nice, France; Centre Antoine Lacassagne, Department of nuclear medicine, Nice, France.
Manuel BardièsUMR 1037 INSERM/UPS, Centre de Recherche en Cancérologie, Toulouse, France.
Georges VassauxLaboratoire TIRO, UMRE 4320, iBEB, DSV, CEA, Nice, France; Université de Nice-Sophia Antipolis, Nice, France; Centre Antoine Lacassagne, Department of nuclear medicine, Nice, France.
Centre Antoine Lacassagne · FRCommissariat à l'Énergie Atomique et aux Énergies Alternatives · FRInserm · FRCentre National de la Recherche Scientifique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Low-energy Auger and conversion electrons deposit their energy in a very small volume (a few nm3) around the site of emission. From a radiotoxicological point of view the effects of low-energy electrons on normal tissues are largely unknown, understudied, and generally assumed to be negligible. In this context, the discovery that the low-energy electron emitter, 99mTc, can induce stunning on primary thyrocytes in vitro, at low absorbed doses, is intriguing. Extrapolated in vivo, this observation suggests that a radioisotope as commonly used in nuclear medicine as 99mTc may significantly influence thyroid physiology. The aims of this study were to determine whether 99mTc pertechnetate (99mTcO4-) is capable of inducing thyroid stunning in vivo, to evaluate the absorbed dose of 99mTcO4- required to induce this stunning, and to analyze the biological events associated/concomitant with this effect. Our results show that 99mTcO4--mediated thyroid stunning can be observed in vivo in mouse thyroid. The threshold of the absorbed dose in the thyroid required to obtain a significant stunning effect is in the range of 20 Gy. This effect is associated with a reduced level of functional Na/I symporter (NIS) protein, with no significant cell death. It is reversible within a few days. At the cellular and molecular levels, a decrease in NIS mRNA, the generation of double-strand DNA breaks, and the activation of the p53 pathway are observed. Low-energy electrons emitted by 99mTc can, therefore, induce thyroid stunning in vivo in mice, if it is exposed to an absorbed dose of at least 20 Gy, a level unlikely to be encountered in clinical practice. Nevertheless this report presents an unexpected effect of low-energy electrons on a normal tissue in vivo, and provides a unique experimental setup to understand the fine molecular mechanisms involved in their biological effects.

Indexed as

AnimalsBiological TransportDNA Breaks, Double-StrandedElectronsFemaleGene Expression RegulationMiceRadiometryRNA, MessengerSodium-Iodide SymportersSodium Pertechnetate Tc 99mSymportersThyroid GlandTomography, Emission-Computed, Single-PhotonTomography, X-Ray ComputedRNA, MessengerSodium-Iodide SymportersSodium Pertechnetate Tc 99mSymporters

Identifiers

PMID24663284
PMCPMC3963936
OpenAlexW1989965771

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.